A unique new flexible and stretchable device, worn against the skin and capable of producing electrical energy by transforming the compounds present in sweat, was recently developed and patented by CNRS researchers from l’Université Grenoble Alpes and UC San Diego (USA). This cell is already capable of continuously lighting an LED, opening new avenues for the development of wearable electronics powered by autonomous and environmentally friendly biodevices.
This research was published in Advanced Functional Materials on September 25, 2019.
The potential uses for wearable electronic devices continue to increase, especially for medical and athletic monitoring. Such devices require the development of a reliable and efficient energy source that can easily be integrated into the human body. Using “biofuels” present in human organic liquids has long been a promising avenue.
Scientists from the Département de chimie moléculaire (CNRS/Université Grenoble Alpes), who specialize in bioelectrochemistry, decided to collaborate with an American team from UC San Diego, who are experts in nanomachines, biosensors, and nanobioelectronics. Together they developed a flexible conductive material consisting of carbon nanotubes, crosslinked polymers, and enzymes joined by stretchable connectors that are directly printed onto the material through screen-printing1.
The biofuel cell, which follows deformations in the skin, produces electrical energy through the reduction of oxygen and the oxidation of the lactate present in perspiration.
Once applied to the arm, it uses a voltage booster to continuously power an LED. It is relatively simple and inexpensive to produce, with the primary cost being the production of the enzymes that transform the compounds found in sweat. The researchers are now seeking to amplify the voltage provided by the biofuel cell in order to power larger portable devices.
The Latest on: Biofuel cell
via Google News
The Latest on: Biofuel cell
- PhageNova Bio, Inc. Announces Publication of Design and Development of Experimental COVID-19 Vaccineson July 7, 2021 at 10:16 pm
PhageNova Bio, Inc. ("PhageNova") is pleased to announce that data related to its proprietary vaccine development program have been published in the Proceedings of the National Academy of Sciences.
- Provention Bio drug for delaying type 1 diabetes hit with FDA delay of its ownon July 7, 2021 at 11:17 am
Provention Bio needs to show the FDA that the drug substance produced from its contract manufacturer is comparable to the Eli Lilly-made drug substance that was evaluated in clinical trials. A larger ...
- Graphite Bio: gene editing blood stem cells for sickle cell diseaseon July 7, 2021 at 4:49 am
Ex vivo gene editing of hematopoietic stem cells using CRISPR–Cas9 and adeno-associated virus serotype 6 is ready for trials in people with sickle-cell disease.
- Inceptor Bio Launches FastBack Bio, Its First Portfolio Company Developing A Novel CAR-T Platform That Targets Difficult-To-Treat Cancerson July 6, 2021 at 11:01 pm
Inceptor Bio, a Research Triangle Park, North Carolina-based cell and gene therapy biotechnology company, announced today that it has launched FastBack Bio, the first of multiple next-generation cell ...
- Bluebird Bio strikes back with counterclaim against Spark Therapeuticson July 6, 2021 at 1:01 pm
"This suit is a misguided exercise by a large pharmaceutical company to assert its trademarks beyond their registered scope, which will disadvantage patients and families living with the devastating ...
- No Batteries? No Sweat! Wearable Biofuel Cells Now Produce Electricity from Lactateon July 6, 2021 at 12:32 pm
Tokyo University of Science has produced biofuel cells that run on sweat so you don't need to worry about charging them.
- Green Science Alliance Has Developed SOFC (Solid Oxide Fuel Cell) Which Can Produce Electricity with Bio-Ethanolon July 6, 2021 at 12:48 am
Green Science Alliance has been developing various types of electrode and solid electrolyte for SOFC. This time, Dr. Hideki Yoshioka and Dr. Ryohei Mori at Green Science Alliance have created SOFC ...
- With sickle cell disease study in sight, Graphite Bio draws up a $238M IPOon June 25, 2021 at 3:08 pm
Gene-editing company Graphite Bio’s $238 million IPO was the biggest in biotech this week as it works toward human tests of a therapy that corrects the genetic mutation behind sickle cell disease.
- Senti Bio, hot off $645M Spark pact, tees up in-house manufacturing for natural killer cell therapieson June 25, 2021 at 6:55 am
Bayer-backed Senti Bio is dropping an undisclosed sum to lease and build-out a manufacturing facility all on its own. Internal manufacturing will prove essential in Senti's quest to maintain ...
- Graphite Bio leads this week's IPO squad, looking to turn the tide on sickle cell disease with gene editingon June 25, 2021 at 6:37 am
Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here. Biotech’s IPO march continued earlier this week with Monte Rosa pricing on Thursday, and now Friday’s ...
via Bing News